Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 12-2008 | 09-2008 | 06-2008 | 03-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,520 | N/A | -36,100 | -30,110 | -22,960 |
| Depreciation Amortization | 61 | N/A | 7,410 | 4,310 | 2,600 |
| Other Working Capital | 612 | N/A | 7,480 | 9,800 | 12,120 |
| Other Operating Activity | 4,556 | 0 | 15,130 | 15,400 | 13,780 |
| Operating Cash Flow | $-12,291 | $N/A | $-6,080 | $-600 | $5,540 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | N/A | -1,930 | -1,690 | -1,050 |
| Other Investing Activity | 43 | 0 | 1,720 | 1,660 | 1,340 |
| Investing Cash Flow | $43 | $N/A | $-210 | $-30 | $290 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 16,563 | 0 | 2,330 | -1,780 | -1,010 |
| Financing Cash Flow | $16,563 | $N/A | $2,330 | $-1,780 | $-1,010 |
| Exchange Rate Effect | -223 | N/A | -150 | -100 | -100 |
| Beginning Cash Position | 8,509 | N/A | 5,800 | 5,800 | 5,800 |
| End Cash Position | 12,602 | N/A | 1,680 | 3,270 | 10,520 |
| Net Cash Flow | $4,093 | $N/A | $-4,110 | $-2,520 | $4,720 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,291 | N/A | -6,080 | -600 | 5,540 |
| Free Cash Flow | -12,291 | 0 | -6,080 | -600 | 5,540 |